Navigation Links
Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care

MirixaPro 2.2 enables the next generation in medication therapy management

and medication adherence services

RESTON, Va., Sept. 17 /PRNewswire/ -- Mirixa Corporation, a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services, today announced the immediate availability of version 2.2 of the MirixaPro(TM) product suite (MirixaPro 2.2). With this latest release of MirixaPro, pharmacies nationwide have fingertip access to an enhanced array of clinical care management tools that streamline pharmacy-based delivery of targeted patient care services including medication therapy management (MTM), medication adherence and disease management.

Leveraging Mirixa's technology, pharmacists have delivered tens of thousands of targeted MTM patient interventions, resolved thousands of alerts indicating potential safety issues and worked actively with patients and physicians to improve medication-related care. Qualifying patient cases are delivered directly and securely to the pharmacist, along with the patient's medication history. MirixaPro's workflow system supports delivery of multiple interventions through a single Web-based interface.

"Medication non-adherence and inadequate medication management is nothing short of a national epidemic," says Eric Zimmerman, Chief Innovation Officer and General Manager of Mirixa Clinical. "About 50% of patients with chronic conditions do not take their medications correctly -- we can and must do far better. At Mirixa, we're convinced the solution starts by levering the 'triangle of trust' between patients, physicians and pharmacists.

"MirixaPro makes collaboration easier by using data to pinpoint care improvement opportunities, monitor progress, and speed the flow of information across a secure network of care. The results so far are encouraging -- every day we hear from pharmacists using our technologies to collaborate with physicians to close gaps in care, resolve safety risks, and help consumers become confident and successful in managing their health," added Zimmerman.

MirixaPro 2.2 will be previewed by industry leaders at the Health 2.0 Conference on September 20 in San Francisco, CA as well as at the NACDS Medication Therapy Management Services in Community Pharmacy Conference September 19-20 in Philadelphia, PA.

About Mirixa

Mirixa Corporation is a leading developer of innovative clinical solutions that facilitate pharmacist-based patient care services and a leader in Medication Therapy Management (MTM) technology solutions. Founded by the National Community Pharmacists Association (NCPA), Mirixa has assembled the largest pharmacy services network of its kind with over 40,000 contracted community pharmacies -- including both independents and chains. Mirixa's technology portfolio empowers the delivery of highly targeted medication management programs, patient education, recruitment campaigns and patient medication records. The company's leadership team shares a vision and passion for improving patient care, reducing overall health costs, and expanding consumer access to accurate medication information. Mirixa is headquartered in the heart of the Dulles Technology Corridor in Reston, VA; with offices in California, Texas and New Jersey. For more information visit

Contact: Liz Deakin

Mirixa Corporation

Phone: 703-600-1226


SOURCE Mirixa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
(Date:10/13/2015)... ... , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that ... March 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... around the world. , Key topics at this year's event will include discussions on ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a ... announced today a significant contract that will provide its award-winning private messaging solution ... on the growing success of its Relay program, IBX Wire™, which now has ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of ... train with, participate in local fitness & sporting events, and stay motivated. ... high medical costs drive us to get more serious about fitness and wellness, individuals ...
(Date:10/13/2015)... Boston, MA (PRWEB) , ... October 13, 2015 , ... ... mortar of the body, including muscle, bone, and blood. But how much protein does ... more complicated than it might seem, according to the October 2015 issue of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Scientists in ... tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted ... , The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Data Science Automation (DSA), ... opening of a new branch office in the ... DSA,s presence in Europe . The decision ... increasing demand for local support of customers in the medical ... Ph.D., DSA,s UK Branch Manager. "We have had tremendous success ...
(Date:10/13/2015)... -- SeraCare Life Sciences, a leading partner to global in ... medicine business unit has launched its second product in ... (NGS)-based tumor profiling assays.  The Seraseq TM Solid ... mutations in key oncogenes and tumor suppressor genes as ... is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13, 2015  Graduate students across ... and medical research, will soon have the opportunity ... care – the drug discovery and development process. ... has collaborated with 10 leaders from academic institutions ... Medicines: The Process of Drug Development."  Lilly will ...
Breaking Medicine Technology: